Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24 2020 - 7:15AM
Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“
Aleafia
Health” or the “
Company”) today announced
that Janssen Pharmaceuticals, Inc. (“
Janssen”),
has approved its wholly owned subsidiary, Canabo Medical Inc.
(“Canabo”) as an administrator and prescriber of antidepressant
SPRAVATO® (esketamine) nasal spray. Three Canabo clinics,
including the Company’s flagship Toronto location, along with a
growing number of clinic network physicians and nurses, are now
approved to administer and prescribe SPRAVATO® following the
Janssen Journey training program’s completion. The Company
intends to further expand this offering at its nationwide network
of clinics and education centres which are staffed by physicians
and nurse practitioners and have served over 70,000 unique patients
to date.
Janssen, a division of Johnson & Johnson (NYSE: JNJ),
received U.S. Food and Drug Administration approval for
SPRAVATO® for use with an oral antidepressant in adults with
treatment-resistant depressive disorder (TRD), followed by the drug
being made available in Canada on July 22, 2020.
According to Janssen, “Health Canada’s approval was based
[on] two pivotal Phase 3 clinical trials; a short-term
induction study and a long-term maintenance study. In the induction
study, those who took SPRAVATO® and an oral antidepressant
experienced a statistically significant improvement in depression
symptoms at four weeks compared to those who received a placebo and
an oral antidepressant.”
“The expansion of Aleafia Health’s services to our existing
and prospective patients speaks to our commitment to improving
the lives of Canadians through innovative, evidence-based
medicine,” said Aleafia Health CEO Geoffrey Benic. “We believe the
skill sets and training of our physicians, the existing
infrastructure of our national clinic network and
our passion for patient access and best-in-class
medicine make Aleafia Health particularly well situated to
administer SPRAVATO®.”
For more information on SPRAVATO® clinical trials,
benefits, risks and side effects, please see
the SPRAVATO® Product Monograph.
For Investor & Media Relations
Nicholas BergaminiVP Investor
Relations1-833-879-2533IR@AleafiaHealth.com
Learn More: www.AleafiaHealth.com
About Aleafia Health
Aleafia Health is a vertically integrated and
federally licensed Canadian cannabis company offering cannabis
health and wellness services and products in Canada and in
international markets. The Company operates medical clinics,
education centres and production facilities for the production and
sale of cannabis.
Aleafia Health owns three significant licensed
cannabis production facilities, including the first large-scale,
legal outdoor cultivation facility in Canadian history. The Company
produces a diverse portfolio of commercially proven, high-margin
derivative products including oils, capsules and sprays. Aleafia
Health operates the largest national network of medical cannabis
clinics and education centres staffed by MDs, nurse practitioners
and educators and operates internationally in three continents.
Innovation, the heart of Aleafia Health’s
competitive advantage, has led to the Company maintaining a medical
cannabis dataset with over 10 million data points to inform
proprietary illness-specific product development and its highly
differentiated education platform FoliEdge Academy. The Company is
committed to creating sustainable shareholder value; the TSX
Venture Exchange named Aleafia the 2019 top performing company
prior to its graduation to the TSX.
About the Janssen Pharmaceutical Companies of Johnson
& Johnson
At Janssen, we're creating a future where disease is a thing of
the past. We're the Pharmaceutical Companies of Johnson &
Johnson, working tirelessly to make that future a reality for
patients everywhere by fighting sickness with science, improving
access with ingenuity, and healing hopelessness with heart. We
focus on areas of medicine where we can make the biggest
difference: Cardiovascular & Metabolism, Immunology, Infectious
Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary
Hypertension.
Learn more at www.janssen.com. Follow us
at www.twitter.com/JanssenGlobal. Janssen Pharmaceuticals,
Inc. is one of the Janssen Pharmaceutical Companies of Johnson
& Johnson.
Forward Looking Information
This news release contains forward-looking
information within the meaning of applicable Canadian and United
States securities laws and are expressly qualified by this
cautionary statement. Often, but not always, forward-looking
information can be identified by the use of words such as “plans”,
“expects” or “does not expect”, “is expected”, “estimates”,
“intends”, “anticipates” or “does not anticipate”, or “believes” or
variations of such words and phrases or state that certain actions,
events or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved. Forward-looking statements in this
news release include, but are not limited to, statements with
respect to injection of value this settlement brings to the
Company’s business. Forward-looking information involves known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company or its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained in this news release. Risks,
uncertainties and other factors involved with forward-looking
information could cause actual events, results, performance,
prospects and opportunities to differ materially from those
expressed or implied by such forward-looking information, including
risks contained in the Company’s annual information form dated
March 18, 2020 which is available on the Company’s SEDAR profile
at www.sedar.com. Although the Company
believes that the assumptions and factors used in preparing the
forward-looking information in this news release are reasonable,
undue reliance should not be placed on such information and no
assurance can be given that such events will occur in the disclosed
time frames or at all. The forward-looking information included in
this news release is made as of the date of this news release and
the Company does not undertake any obligation to publicly update
such forward-looking information to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024